Imipenem-cilastatin as initial therapy for febrile cancer patients.
AUTOR(ES)
Bodey, G P
RESUMO
Imipenem-cilastatin was used to treat 79 febrile episodes in 71 cancer patients, most of whom had neutropenia. The overall response rate was 67%, and 76% of the 45 documented infections responded. The response rates for septicemias and pneumonias were 79 and 62%, respectively. Only 1 of the 17 infections caused by gram-negative bacilli failed to respond to this therapy. The most common side effects were skin rash, nausea, and diarrhea. Eight superinfections were detected during therapy.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=180520Documentos Relacionados
- Ceftazidime versus imipenem-cilastatin as initial monotherapy for febrile neutropenic patients.
- Biliary excretion of imipenem-cilastatin in hospitalized patients.
- Effect of imipenem-cilastatin therapy on fecal flora.
- Safety and efficacy of high-dose treatment with imipenem-cilastatin in seriously ill patients.
- Pharmacokinetics of imipenem-cilastatin in neonates.
